Seres $MCRB is taking another step forward in its comeback effort on a microbiome drug that rattled everyone in the field when it failed a mid-stage study. The biotech says that it has learned from its setback and has now started a study for patients with multiple recurrent C. difficile infection that it’s hoping will serve as the pivotal Phase III for SER-109. That move — the most advanced microbiome study in the gut research world — was worth a $20 million milestone payment from its partners at Nestlé Health Science.
The best place to read Endpoints News? In your inbox.
Comprehensive daily news report for those who discover, develop, and market drugs. Join 41,800+ biopharma pros who read Endpoints News by email every day.Free Subscription